G1 Therapeutics Inc
NASDAQ:GTHX
G1 Therapeutics Inc
NASDAQ:GTHX
Price:
4.55 USD
0.44%
Market Closed
Updated:
May 21, 2024
G1 Therapeutics Inc
Selling, General & Administrative
|
G1 Therapeutics Inc
Selling, General & Administrative Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
G1 Therapeutics Inc
NASDAQ:GTHX
|
Selling, General & Administrative
-$64.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$13B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$6.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-23%
|
See Also
What is G1 Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-64.5m
USD
-64.5m
USD
Based on the financial report for Mar 31, 2024, G1 Therapeutics Inc's Selling, General & Administrative amounts to -64.5m USD.
What is G1 Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-23%
-23%
Over the last year, the Selling, General & Administrative growth was 32%. The average annual Selling, General & Administrative growth rates for G1 Therapeutics Inc have been 7% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
